Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.

To test whether a dementia drug could improve cognition in breast cancer survivors, researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer's disease.

The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.

The findings appear online in the Journal of Clinical Oncology.

The researchers enrolled 276 breast cancer survivors from community oncology practices affiliated with the National Cancer Institute Community Oncology Research Program (NCORP), a national network that brings cancer clinical trials and care delivery studies to communities. The Wake Forest NCORP Research Base at Atrium Health Wake Forest Baptist's National Cancer Institute-designated Comprehensive Cancer Center is one of seven funded NCORP Research Program bases in the country.

Study participants had received at least four cycles of adjuvant chemotherapy and reported cognitive impairment and memory problems for one to five years after chemotherapy had completed. Participants were enrolled on the NCORP study between July 2017 and July 2021.

The participants were assigned to either receive 5-10 mg of donepezil, taken once a day for 24 weeks, or placebo."

Stephen R. Rapp, Ph.D., professor of psychiatry and behavioral medicine at Wake Forest University School of Medicine and lead author of the paper

Cognitive assessments were conducted before treatment, at 12 weeks and at end of treatment.

"We found that the participants did not perform differently at the end of treatment on tests of memory, other cognitive functions, or subjective functioning than those randomly assigned to placebo," Rapp said.

While donepezil cannot be recommended as a treatment to improve cancer-related cognitive impairment in breast cancer survivors after completing chemotherapy, the researchers say further trials are needed.

"Additional research with different timing of administration, different medications or medication combinations, or non-pharmacological interventions are warranted," said Glenn Lesser, M.D., deputy director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center, senior author of the manuscript and principal investigator of the Wake Forest NCORP Research Base.

Source:
Journal reference:

Rapp, S. R., et al. (2024). Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116). Journal of Clinical Oncology. doi.org/10.1200/jco.23.01100.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New brain connectivity model predicts dementia years before diagnosis